In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
New targeted therapies for relapsed or refractory mantle cell lymphoma
In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read MoreVenetoclax for patients with relapsed/refractory chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the safety of venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax is safe in these patients as a long-term continuous therapy. Some background Venetoclax is a treatment used for patients with relapsed/refractory (RR)...
Read MoreBrentuximab vedotin: a study of its safety for unresponsive Hodgkin lymphoma.
In a nutshell This study aimed to analyse the side effects associated with brentuximab vedotin (BV; Adcetris) treatment for patients with Hodgkin lymphoma (HL) who had undergone stem cell transplantation (SCT) that is now unresponsive to treatment. The main side effects identified included nerve damage, infections and low white blood cell...
Read MoreIs busulfan a useful drug to improve successful transplantation in the treatment of acute leukemia?
In a nutshell This study looked at the effect of using busulfan to delete blood cancer cells from the system before replacing them with normal cells in the treatment of leukaemia. The study found that busulfan therapy was effective in removing blood cancer cells before replacement, in the treatment of high-risk acute leukaemia. Some background Acute...
Read MoreLenalidomide and dexamethasone in relapsed/refractory multiple myeloma
In a nutshell This study examined the effect of lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma. This study concluded that the treatment combination was effective and results were similar to that seen in clinical trials. Some background Lenalidomide is a type of immunotherapy (stimulates the immune system to fight...
Read MoreWhat are the effects of treatment with brentuximab vedotin plus bendamustine on unresponsive HL?
In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...
Read MoreDoes ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...
Read MoreWhat type of stem cell transplant is most effective after early treatment failure in follicular lymphoma?
In a nutshell This study investigated the effectiveness of stem cell transplantation in follicular lymphoma patients who experienced early treatment failure after frontline chemoimmunotherapy. This study concluded that transplants using the patient's own stem cells or those from a matched sibling donor lead to better survival outcomes in these...
Read MoreRadiotherapy for relapsed or refractory diffuse large b-cell lymphoma
In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...
Read MoreTargeted immunotherapies for classical Hodgkin’s lymphoma
In a nutshell This article reviewed the results of new targeted immunotherapy treatments in patients with classical Hodgkin’s lymphoma that is relapsed or refractory (does not respond to treatment). Some background Thanks to treatment advances, classical Hodgkin’s lymphoma (cHL) has become one of the most curable cancers. Frontline ABVD...
Read MoreIs targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?
In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...
Read More